He completed his medical oncology training in Brisbane, Australia and then pursued a clinical research fellowship in the BRAS Drug Development Program at Princess Margaret Cancer Centre (PM). Following completion of his fellowship he was appointed as an Assistant Professor of Medicine at the University of Toronto and a Staff Medical Oncologist at PM in 2015. His tumor sites of interest include head and neck cancers and genitourinary (GU) tumors. Currently his is the medical oncology site lead for the GU site.
The principal goals of his career are to develop new anticancer therapies and to evaluate health related quality of life (HRQOL) and patient reported outcomes in both phase I patients and those treated with immunotherapies. He has been the PI for phase I, II and III trials in head and neck and GU cancers. He has led a study to develop a PRO tool to measure HRQOL in patients treated with immune checkpoint therapies called FACT-ICM. This tool is currently undergoing validity testing. In addition he has led a study to administer the PROCTCAE to patients on experimental therapy and is mapping PROCTCAE responses to clinician reported events to define the clinical actionability of PROCTCAE items. He is a member of the QOL and IND committees at CCTG and is a member of the NCI recurrent metastatic head and neck cancer committee.